|
1
|
Gkioka AI, Tsota M, Koudouna A, Gkiokas A, Mitropoulou CA, Palaiokrassa A, Alexandropoulos A, Papadatou-Gigante M, Bartzi V, Tryfou TM, Sfikakis PP, Dedoussis GV, Kyrtsonis MC. Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment. Int J Mol Sci 2024; 25:6065. [PMID: 38892251 PMCID: PMC11172882 DOI: 10.3390/ijms25116065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2024] [Revised: 05/30/2024] [Accepted: 05/30/2024] [Indexed: 06/21/2024] Open
Abstract
MicroRNAs (miRNAs), particularly miR-16 and miR-21, play a crucial role in multiple myeloma (MM) pathogenesis by regulating gene expression. This study evaluated the prognostic significance of circulating miR-16 and miR-21 expression levels in 48 patients with MM at diagnosis treated with lenalidomide-dexamethasone (LD) compared with 15 healthy individuals (HI). All patients were treated with LD, 13 at first line and 35 at relapse, of whom 21 were tested twice at diagnosis and before LD initiation. The results revealed significantly lower levels of miR-16 and miR-21 in patients than in HIs, both at diagnosis and relapse, with decreased miR-16 levels at diagnosis, indicating improved overall survival (OS) (p value 0.024). Furthermore, miR-16 and miR-21 levels were associated with disease markers, while both correlated with the depth of response and mir-16 with sustained response to LD treatment. Ratios of both miR-16 and miR-21 expression levels (prior to LD treatment/diagnosis) below two predicted a shorter time to response (p = 0.027) and a longer time to next treatment (p = 0.042), respectively. These findings suggested a prognostic value for serum miR-16 and miR-21 levels in MM, as their expression levels correlated with disease variables and treatment outcomes.
Collapse
Affiliation(s)
- Annita-Ioanna Gkioka
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Maria Tsota
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17676 Athens, Greece; (M.T.); (C.-A.M.); (A.P.)
| | - Aspasia Koudouna
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Alexandros Gkiokas
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Christina-Aggeliki Mitropoulou
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17676 Athens, Greece; (M.T.); (C.-A.M.); (A.P.)
| | - Aikaterini Palaiokrassa
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17676 Athens, Greece; (M.T.); (C.-A.M.); (A.P.)
| | - Alexandros Alexandropoulos
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Mavra Papadatou-Gigante
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Vasiliki Bartzi
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Thomais-Marina Tryfou
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - Petros P. Sfikakis
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| | - George V. Dedoussis
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17676 Athens, Greece; (M.T.); (C.-A.M.); (A.P.)
| | - Marie-Christine Kyrtsonis
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens’ Medical School, 11527 Athens, Greece; (A.-I.G.); (A.K.); (A.G.); (A.A.); (M.P.-G.); (V.B.); (T.-M.T.); (P.P.S.)
| |
Collapse
|
|
2
|
Listro R, Stotani S, Rossino G, Rui M, Malacrida A, Cavaletti G, Cortesi M, Arienti C, Tesei A, Rossi D, Giacomo MD, Miloso M, Collina S. Exploring the RC-106 Chemical Space: Design and Synthesis of Novel ( E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. Front Chem 2020; 8:495. [PMID: 32695745 PMCID: PMC7338850 DOI: 10.3389/fchem.2020.00495] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 05/14/2020] [Indexed: 01/19/2023] Open
Abstract
Despite the fact that significant advances in treatment of common cancers have been achieved over the years, orphan tumors still represent an important unmet medical need. Due to their complex multifactorial origin and limited number of cases, such pathologies often have very limited treatment options and poor prognosis. In the search for new anticancer agents, our group recently identified RC-106, a Sigma receptor modulator endowed with proteasome inhibition activity. This compound showed antiproliferative activity toward different cancer cell lines, among them glioblastoma (GB) and multiple myeloma (MM), two currently unmet medical conditions. In this work, we directed our efforts toward the exploration of chemical space around RC-106 to identify new active compounds potentially useful in cancer treatment. Thanks to a combinatorial approach, we prepared 41 derivatives of the compound and evaluated their cytotoxic potential against MM and GB. Three novel potential anticancer agents have been identified.
Collapse
Affiliation(s)
- Roberta Listro
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy
| | - Silvia Stotani
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy.,Medicinal Chemistry, Taros Chemicals GmbH and Co. KG, Dortmund, Germany
| | - Giacomo Rossino
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy
| | - Marta Rui
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy
| | - Alessio Malacrida
- Experimental Neurology Unit, School of Medicine and Surgery & Milan Center for Neuroscience, University of Milan Bicocca, Monza, Italy
| | - Guido Cavaletti
- Experimental Neurology Unit, School of Medicine and Surgery & Milan Center for Neuroscience, University of Milan Bicocca, Monza, Italy
| | - Michela Cortesi
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRCCS), Meldola, Italy
| | - Chiara Arienti
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRCCS), Meldola, Italy
| | - Anna Tesei
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRCCS), Meldola, Italy
| | - Daniela Rossi
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy
| | - Marcello Di Giacomo
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy
| | - Mariarosaria Miloso
- Experimental Neurology Unit, School of Medicine and Surgery & Milan Center for Neuroscience, University of Milan Bicocca, Monza, Italy
| | - Simona Collina
- Medicinal Chemistry and Pharmaceutical Technology Section, Department of Drug Sciences, University of Pavia, Pavia, Italy
| |
Collapse
|